The Leader in Nasal Decolonization

 

Watch the Video!

See how clinically proven Nozin IP Programs can reduce infection, improve patient care and lower costs.

 

Evidence

Evidence shows that nasal bacteria are a primary component in the spread of infection.

%

30% of population carry Staph aureus in the nose⁸

%

80% of wound infections traced by DNA to bacteria in the patients' own nose⁹

%

44% reduction in ICU infections with universal nasal and skin decolonization³

%

81% infection reduction with Nozin 360™ added to an existing IP bundle²

Nasal Decolonization White Papers

Healthcare professionals are invited to download our FREE white papers on the nasal decolonization landscape.

Emerging Strategies on Achieving Nasal DecolonizationNasal Decolonization's Broadening Application

 

Emerging Strategies on Achieving Nasal Decolonization For Reducing Hospital Acquired Infections
& Nasal Decolonization's Broadening Application: Replacing Contact Precautions

News and Major Published Articles

Baylor SSI Study Published²

Perioperative participation of orthopedic patients and surgical staff in a nasal decolonization intervention to reduce Staphylococcus...

IDSA Annual Meeting

Baylor Orthopedic and Spine Hospital at Arlington presented results of a study entitled: Pre- and Post-Operative Participation of Orthopedic Patients...

Nozin Effective in Treating Staph aureus Nasal Carriage

MarketWatch  has published the press article: “Nozin Antiseptic Drug Effective in Treating Staph aureus Nasal Carriage”

Nasal Decolonization and HAI Prevention

New article by Sue Barnes, RN, CIC, the former national program leader for infection prevention at Kaiser Permanente. Click below to view full article.

APIC 2016 Conference

Nina Deatherage, BSN, RN, PHN, CIC, and Infection Control Lead at Marshall Medical Center presented results of eliminating MRSA contact precautions at Marshall.

Reduction of nasal Staphylococcus aureus carriage¹

The American Journal of Infection Control (AJIC) has in press the article: “Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based...

Strength in Numbers

In this article the author, Valerie Dimond, makes a case for stronger cooperation in achieving goals of Antimicrobial Stewardship Programs (ASPs).

MRSA at Marshall Medical Center

Reuters is among a number of news outlets that have run the press article: “Nozin Nasal Drug Reduces Risk and Cost Associated with MRSA at Marshall...

Visit NozinPro.com for Additional Research and Information

Visit NozinPro.com for additional Information and Research. NozinPro.com is a health professional resource site.

References

1. Steed LL et al. Am J Infect Control 2014; 42:841-846.
2. Mullen A et al. Am J Infect Control 2017; 45(5):554-556.
3. Huang SS et al. N Engl J Med 2013; 368(24):2255-2265.
4. Deatherage N. Am J Infect Control 2016; 44(6) Supplement, S101-S102.
5. Huang SS et al. Infect Control Hosp Epidem 2014; 35(S3):S23-S31.
6. Kalmeijer MD et al. Infect Control Hosp Epidem 2000; 21:319-323.
7. Thakkar V et al. Clin Neurol Neurosurg 2014; 125:94-97.
8. Werthheim HFL et al. Lancet 2005; 5:751-762.
9. Coates T et al. J Antimicrob Chemother 2009; 64:9-15.
10. Tammelin A et al. Infect Control Hosp Epidemiol 2003; 24(9):686-689.


Health Professionals:
Request Nozin® samples for your facility.

© 2004-2018 Global Life Technologies Corp. All rights reserved. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease. | Privacy Policy